menu
    • menu
    [{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Polaris Innovation Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Pin1","graph1":"Oncology","graph2":"Discovery","graph3":"Larkspur Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Larkspur Biosciences \/ Polaris Innovation Fund","highestDevelopmentStatusID":"2","companyTruncated":"Larkspur Biosciences \/ Polaris Innovation Fund"},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LRK-A","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Larkspur Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larkspur Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Larkspur Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Larkspur Biosciences

    Menu

    Larkspur Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Larkspur Biosciences

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Larkspur Biosciences

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LRK-A

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Larkspur Presents Preclinical Research on First-in-Class PIP4K2C Degrader at AACR

                            Details : LRK-A is a novel, lead investigational therapy targeting the lipid kinase PIP4K2C, which is being evaluated for the treatment of patients with colorectal cancer.

                            Product Name : LRK-A

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2024

                            Lead Product(s) : LRK-A

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Larkspur Biosciences

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed

                            Larkspur Biosciences

                            U.S.A arrow
                            China Battery Fair
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Polaris Innovation Fund

                            Deal Size : $35.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to O...

                            Details : The financing will focus on IND-enabling for company's lead program, a cutting-edge approach to lipid remodeling to uncloak tumors and preclinical studies for its first-in-class program targeting Pin1, a key mechanism of fibroblast differentiation to act...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Polaris Innovation Fund

                            Deal Size : $35.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth